Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer

• Published in: Scientific reports Vol. 13; no. 1; p. 16663
• Main Authors: Shin, Won Sik, Han, Seung Hyun, Jo, Kyung Won, Cho, Yunje, Kim, Kyong-Tai
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04.10.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154; 631/45; 631/67; 631/80; Alternative splicing; Androgen receptors; Androgens; Castration; Cell viability; Gene expression; Humanities and Social Sciences; multidisciplinary; Prostate cancer; Science; Science (multidisciplinary); Sex hormones
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-43561-5

Prostate cancer is the most prevalent cancer in men worldwide and is promoted by the sex hormone androgen. Expression of androgen from the testis can be significantly reduced through castration. However, as most prostate cancer patients acquire castration resistance, additional therapeutic solutions are necessary. Although anti-androgens, such as enzalutamide, have been used to treat castration-resistant prostate cancer (CRPC), enzalutamide-resistant CRPC (Enz-resistant CRPC) has emerged. Therefore, development of novel treatments for Enz-resistant CRPC is urgent. In this study, we found a novel anti-androgen called pinostilbene through screening with a GAL4-transactivation assay. We confirmed that pinostilbene directly binds to androgen receptor (AR) and inhibits its activation and translocalization. Pinostilbene treatment also reduced the protein level and downstream gene expression of AR. Furthermore, pinostilbene reduced the protein level of AR variant 7 in the Enz-resistant prostate cancer cell line 22Rv1 and inhibited cell viability and proliferation. Our results suggest that pinostilbene has the potential to treat Enz-resistant CRPC.